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Utilizing formalin-fixed paraffin-embedded (FFPE) archival tissue, the most common 
form of tissue preservation in routine practice, for cytogenetic analysis using microarray 
comparative genomic hybridization (aCGH) remains challenging. We searched for a 
predictive factor of the performance of FFPE DNA in aCGH analysis. DNA was 
extracted from 63 FFPE archival tissue samples of various tissue types (31 breast 
cancers, 24 lung cancers and 8 thyroid tumors), followed by aCGH analysis using 
high-density oligonucleotide microarrays. Tumor DNA from matched frozen samples, 
and from FFPE samples following whole genome amplification (WGA) were also 
analyzed in two and four case, respectively. The derivative log ratio spread 
(DLRSpread) was used to assess the overall quality of each aCGH result. The 
DLRSpread correlated significantly with the double-stranded DNA ratio of tumor DNA, 
storage time and the degree of labeling with Cy5 (P < 0.0001, correlation coefficients = 
-0.796, 0.551, -0.481, respectively). Stepwise multiple linear regression analysis 
revealed that the double-stranded DNA ratio of tumor DNA is the most significant 
predictive factor of DLRSpread (regression coefficient = -0.4798, P-value = < 0.0001). 
The cytogenetic profiles of FFPE and matched frozen samples showed good concordance. 
Although the double-stranded DNA ratios were increased after WGA, the DLRSpread 
was not improved. The double-stranded DNA ratio can be used to predict aCGH 
analysis performance for DNA from FFPE samples. Using this quality metric, valuable 









Comparative genomic hybridization (CGH) is an especially useful method for detecting 
chromosomal instability in tumor genomes, an important hallmark of cancer(1). Recent 
technological advances have enabled higher resolution CGH analysis through the use of 
high-density microarrays(2-10). However, utilizing formalin-fixed paraffin-embedded 
(FFPE) archival tissue for aCGH remains challenging because of DNA degradation, 
cross-linking between nucleic acid strands, formation of DNA adducts with histones or 
nucleic acid binding proteins, and breaking and depurination of DNA(11, 12).  
Several groups have demonstrated the feasibility of performing aCGH analysis on DNA 
extracted from FFPE samples(13-20). FFPE is the most common form of tissue 
preservation in routine practice and these samples are often associated with detailed 
pathological data and clinical outcomes. Regarding the technical improvement in aCGH 
analysis with FFPE tissue, DeVries et al. reported that whole genome amplification 
(WGA) of DNA isolated from FFPE tissue, by random priming, is robust and 
reproducible(21). Lyons-Weiler et al. presented a modified protocol for single nucleotide 
polymorphism arrays and generated comparable results for fresh frozen tissues(22). 
Meanwhile, Hostetter et al. reported an improvement in aCGH analysis results for 
long-oligonucleotide microarrays when using DNase treatment to generate randomly 
fragmented DNA(23). Furthermore, Wang et al. showed that molecular inversion probe 
microarrays required small intact DNA and was suitable for aCGH analysis using 
FFPE samples(24). Recently, a one-step chemical labeling method, called the Universal 
Linkage System (ULS), was developed where DNA is fluorescently labeled at the N7 
position of guanine without the need for enzymatic reaction, which is susceptible to the 
effects of DNA degradation, yielding precise, robust and high-quality aCGH data(25-27). 
However, a suitable predictor of the performance of DNA from FFPE samples in aCGH, 
which will prevent the wasting of sparse clinical samples and economic resources, is 
still lacking. Certain research groups have reported that a prequalifying PCR test can 
predict the performance of FFPE DNA on microarrays better than FFPE sample age(28, 
29).  
In this retrospective observational study, we search for a factor to predict performance 
of FFPE DNA in aCGH analysis by dissecting aCGH analysis results from 63 archival 
FFPE tissue samples and show that the ratio of double-strand DNA to total DNA 
(dsDNA ratio) is able to predict the performance of FFPE DNA in aCGH analysis better 
than other factors such as FFPE sample age. This quality metric simplifies aCGH 




MATERIALS AND METHODS 
Tumor samples and clinical information 
Sixty-three formalin fixed paraffin embedded (FFPE) tissue samples were obtained 
from the Department of Pathology, Nagasaki University Hospital. The samples included 
31 invasive breast cancers, 24 adenocarcinoma of the lung and 8 thyroid follicular 
tumors. Twenty-eight of the 31 invasive breast cancers and the 24 lung cancers formed 
part of the data set that we previously reported(30, 31). Resected specimens were 
immediately fixed in 10% neutral buffered formalin for 24 hours, processed and 
embedded into paraffin blocks. Routine Hematoxylin and Eosin (H&E) stains were 
performed on 3μm sections of tissue cut from the FFPE blocks. Pathological diagnoses 
were made by independent pathologists. For the breast cancer samples, Fluorescence in 
situ hybridization (FISH) analysis of the HER2 gene was conducted. A minimum 2-fold 
increase in HER2 signals over chromosome enumeration probe 17 (CEP17) signals in 
cancer cells was considered positive for gene amplifications. Storage times for FFPE 
samples ranged between 1 and 43 years, with a mean of 14.5 years. A summary of these 
samples is provided in Supplementary Table 1. Matched fresh frozen tissue samples 
were available for two of the invasive breast cancer samples. All experimental 
procedures for this study were approved by the Committee for Ethical Issues on the 
Human Genome and Gene Analysis in Nagasaki University. 
 
DNA extraction 
Tumor DNA was extracted from each FFPE sample, as previously reported(32). Briefly, 
samples were macrodissected using between 10 and 20 10-μm-thick sections. Tumor 
tissue areas containing more than 70% tumor cells, as identified by a guide slide stained 
with hematoxylin, were selected and manually dissected using surgical scalpels. 
Paraffin removal was performed in 80% xylene after which samples were washed twice 
with absolute ethanol. Deparaffinized tissue pieces were spun down, after which the 
dried up pellet was resuspended in 360μL buffer ATL (QIAmp DNA Mini Kit, Qiagen, 
Dusseldorf, Germany) and incubated at 95 °C for 15 min. Samples were allowed to cool 
down to room temperature and subsequently digested with proteinase K for 3 days at 
56 °C in a rotation oven with periodic mixing and adding of fresh proteinase K every 24 
h. DNA was extracted using the QIAmp DNA Mini Kit according to the manufacturer’s 
instructions with some modifications. Briefly, 400μL buffer AL was added to the sample, 
which was then incubated at 70 °C for 10 min followed by the addition of 400μL 
absolute ethanol and mixing by vortex. The sample solution was placed into the spin 
column followed by centrifugation for 1 min at 8000 ×g. The spin column was washed 
twice with 500μL buffer AW1 by centrifugation at 8000 ×g for 1 min and washed with 
80% ethanol by centrifugation at 14,000 ×g for 3 min. Finally, the DNA was eluted with 
55μL nuclease free water.  
For frozen tissue samples, three to four pierce of tumor tissue were collected and DNA 
was isolated using the QIAmp DNA Mini Kit according to the manufacturer’s 
instructions. For 4 of the breast cancer samples, 100ng DNA extracted from FFPE 
tissue was used in each case for whole-genome amplification using the GenomePlex 
Complete Whole Genome Amplification Kit (Sigma-Aldrich, St. Louis, MO) followed by 
purification using the GenElute PCR Clean-up Kit (Sigma-Aldrich) following the 
manufacturer’s instructions, so that the ratio of double-strand to total DNA (dsDNA 
ratio) of the samples increased.  
DNA was quantitated using the ratio of absorbance at 260 and 280nm (A260/A280), and 
260 and 230nm (A260/A230) on a Nano Drop ND-2000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). The double-strand DNA concentration in each sample 
was quantitated on a Qubit fluorometer with the Qubit dsDNA HS Assay Kit (Life 
Technologies, Carlsbad, CA) following the manufacturer’s instructions.  
 
aCGH analysis 
The Genomic DNA ULS Labeling Kit (Agilent Technologies, Palo Alto, CA) was used to 
chemically label 500ng of DNA from each sample and 250ng of reference female genomic 
DNA (Promega, Madison, WI) with Cy5 or Cy3 dye for 30 min at 85 °C, respectively, 
followed by purification using Agilent-KREApure™ columns. The amount of input DNA 
was determined on a Qubit fluorometer using the Qubit dsDNA HS Assay Kit. The 
degree of Cy5 labeling (absorbance at 650nm) was calculated using a Nano Drop 
ND-2000 spectrophotometer. Purified, labeled samples were then combined and mixed 
with human Cot-1 DNA (Invitrogen, Carlsbad, CA), Agilent 10× Blocking Agent and 
Agilent 2× Hybridization Solution. Prior to array hybridization, hybridization mixtures 
were denatured at 95 °C for 3 min and incubated at 37 °C for 30 min. Agilent CGHblock 
was added and samples were hybridized to the SurePrint G3 Human CGH 8×60K 
Microarray, which contains 8 identical arrays consisting of ~63,000 in situ synthesized 
60-mer oligonucleotide probes that span coding and noncoding sequences with an 
average spatial resolution of ~54 kb. Hybridization was carried out at 65 °C for 40 h 
before washing with Agilent Oligo aCGH Wash Buffer 1 at room temperature for 5 min, 
followed by washing with Agilent Oligo aCGH Wash Buffer 2 at 37 °C for 1 min. 
Scanning and image analysis were done on an Agilent DNA Microarray Scanner. 
Agilent Feature Extraction Software (version 9.5) was used for data extraction from raw 
microarray image files. Agilent Genomic Workbench (version 5.0) was used to visualize, 
detect and analyze chromosomal patterns using the Aberration Detection Method 2 
(ADM-2) algorithm with the default settings. The derivative log ratio spread 
(DLRSpread) of each sample was also calculated using Agilent Genomic Workbench 




The DLRSpread, which estimates the log ratio noise by calculating the spread of log 
ratio differences between consecutive probes along all chromosomes, was used to assess 
the overall quality of each aCGH result, thus, lower is better. 
To search for predictive factors of the performance of FFPE DNA in aCGH analysis, the 
Spearman rank-correlation was used to evaluate the relationship between DLRSpread 
and A260/A280 ratio, A260/A230 ratio, dsDNA ratio, storage time and degree of labeling 
(Cy5) for each sample. For the DLRSpread, multiple regression analysis with stepwise 
selection was used to examine the associations with A260/A280 ratio, A260/A230 ratio, 
dsDNA ratio, storage time and degree of labeling (Cy5) for each sample. These 
statistical analyses were performed using SAS statistical software (version 9.2, SAS 
Institute Inc., Cary, NC). Reported p-values are two-sided and those < 0.05 were 





Regarding the quality of DNA extracted from FFPE tissue, the mean dsDNA, A260/280 
and A260/A230 ratios were 0.30 (0.017 and 0.79), 1.84 (1.68 and 2.01) and 2.03 (0.92 and 
2.28), respectively, with minimum and maximum values indicated in parentheses. After 
labeling with Cy5, the mean degree of labeling of DNA was 1.30 (0.27–2.02). Finally, the 
mean DLRSpread was 0.45 (0.20–1.05). Conversely, the mean dsDNA ratio, A260/A280 
ratio, A260/A230 ratio, degree of labeling and DLRSpread for DNA extracted from fresh 
frozen tissue was 0.87 (0.77 and 0.96), 1.84 (1.83 and 1.84), 2.09 (2.02 and 2.16), 1.73 
(1.72 and 1.74) and 0.18 (0.17 and 0.19), respectively (Supplementary Table 1).  
For the 2 breast cancer cases for which matched fresh frozen tissue was available, the 
cytogenetic profiles of FFPE and matched fresh frozen samples showed good 
concordance (Figure 1). For the 31 breast cancer samples, we compared the 
amplification status results for HER2 from aCGH and FISH to confirm the validity of 
using FFPE samples for aCGH. HER2 amplification was identified in 11 of 28 samples 
using FISH. Using aCGH, 8 of these 11 samples had log2 ratios > 0.25 for probe sets 
corresponding to the HER2 gene (A_14_P121276, A_14_P114826 and triplicate of 
A_16_P20643178), which met our criteria for a copy number gain. The sensitivity, 
specificity and overall accuracy for the HER2 gene were 81.8%, 94.1% and 89.3%, 
respectively (Supplementary Table 1).  
 
Investigating predictive factors of DLRSpread 
To determine factors predictive of DLRSpread, Spearman rank correlations between 
DLRSpread and the other factors were calculated. The dsDNA ratio and degree of 
labeling of DNA (Cy5) were significantly negatively correlated (P < 0.0001, rs = -0.796, 
-0.481, respectively) whereas storage time was significantly positively correlated (P < 
0.0001, rs= 0.551) with DLRSpread. The A260/A280 ratio was positively correlated 
though not significantly so (P = 0.0589, rs = 0.237) (Table 1).  
To elucidate the effect of each factor on DLRSpread, stepwise multiple linear regression 
analysis was conducted because each factor correlated with each other factor to some 
extent (Table 2). The adjusted R2 value was 0.53. Of the selected variables, the dsDNA 
ratio had the most significant effect on DLRSpread (regression coefficient -0.4798 ± 
0.0914, P < 0.0001), while the degree of labeling of DNA (Cy5) had a mild yet significant 
effect on DLRSpread (regression coefficient -0.1796 ± 0.047, P = 0.0003) (Figure 2, Table 
3).  
 
The effect of WGA on aCGH analysis 
For the 4 FFPE breast cancer samples for which WGA was performed, the dsDNA ratio 
for each sample was successfully increased. However, the degree of DNA labeling (Cy5) 
was slightly decreased and the DLRSpread was increased compared with the original 
DNA (Table 4, Figure 1). Thus, the increase in dsDNA ratio by whole-genome 
amplification did not improve the quality of aCGH analysis using DNA extracted from 




The wealth of clinical samples and comprehensive clinical information, such as clinical 
outcomes, associated with FFPE archival tissue, make these samples an attractive 
source for research. In fact, scarce clinical samples are often only available in FFPE as 
opposed to snap frozen form. However, utilizing FFPE tissues for molecular cytogenetic 
analysis is challenging because of DNA degradation caused by exposure to 
formaldehyde and acidic environments associated with the fixation and preservation 
process. Enzymatic fluorescence labeling is especially susceptible to the effects of DNA 
degradation. The ULS labeling system, which labels DNA non-enzymatically, is 
therefore an ideal method for aCGH analysis with degraded samples.  
In this study, we conducted aCGH analysis on various types of cancer archival tissue 
samples using the ULS labeling system. Our aCGH results, which had a mean 
DLRSpread of 0.45 and an overall accuracy of 89.3% for the HER2 gene, were 
comparable to the results from former aCGH studies using FFPE archival tissue, 
though relatively lower in quality compared to that expected from DNA from fresh 
frozen tissue or peripheral blood lymphocytes(16, 17, 23). Remarkably, very old archival 
tissue, preserved for more than 20 years, could still generate meaningful data. 
Nevertheless, FFPE samples tend to generate poor aCGH results, which indicate the 
importance of identifying a predictive factor for the performance of FFPE DNA in aCGH 
analysis.  
According to the manufacturer’s instructions for ULS labeling, sample quality is only 
assessed by A260/A280 and A260/A230 ratios before labeling, thus DNA samples which 
show A260/A280 ratios of 1.8 to 2.0 and A260/A230 ratios > 2.0 are considered 
high-quality samples. The degree of labeling is used as a quality criterion for aCGH 
results with optimal ranges for Cy5 and Cy3 between 0.75% and 2.5%, and between 
1.75% and 3.5% respectively, with a Cy3 minus Cy5 range between 1% and 2%. However, 
our investigation revealed that neither the A260/A280 nor the A260/A230 ratio could 
predict aCGH performance. The degree of labeling indeed predicted aCGH performance, 
but it cannot predict aCGH performance before the labeling step. Furthermore, 
stepwise multiple linear regression analysis revealed that the dsDNA ratio was the 
most significant predictive factor of aCGH performance. According to the 
manufacturer’s instructions for the ULS labeling system, the DLRSpread for FFPE 
samples should be less than 0.4, which corresponds to a dsDNA ratio of 0.3 according to 
our results. Hence, extremely old samples can be used for aCGH analysis when using 
the ULS labeling system, as long as the dsDNA ratio is > 0.3.This finding is profoundly 
useful because we can predict aCGH performance before the labeling step. This enables 
the user to predict which archival samples will generate high-quality data before 
processing the samples, without wasting scarce specimen and financial resources.  
From our results, we hypothesized that an increase in dsDNA ratio could improve 
aCGH performance when using the ULS labeling system. We then employed the 
GenomePlex Whole Genome Amplification Kit, which generates a representative 500 
fold amplification of genomic DNA using universal primers and optimized enzymes that 
decreases the background in the reaction(33), to enlarge the dsDNA ratio of FFPE 
samples and compared the aCGH results. Disappointingly, the increase in dsDNA ratio 
did not translate to an improvement in DLRSpread, indicating that the poor 
performance of degraded DNA on aCGH platforms could not be attributed to the dsDNA 
ratio, but that the dsDNA ratio was an indicator of the degree of DNA degradation in 
the sample.  
Recently, next generation sequencing technologies have enabled novel findings with 
regards to the molecular architecture of human cancers (34-39). These technologies 
allow detection of not only DNA sequence changes, but also structural changes and copy 
number changes (40, 41) – and can be used in routine clinical practice in some cases (42). 
However, these technologies require high grade DNA extracted from fresh or frozen 
samples which is difficult to obtain, especially for rare patient cases. Furthermore, it 
remains costly to analyze and interpret huge data sets obtained through these 
technologies, although the related running costs are decreasing. On the other hand, 
degraded DNA extracted from FFPE samples can be used for conventional Sanger 
sequencing and aCGH analysis, which may be sufficient for some molecular genetics 
analyses. Furthermore, the cost of aCGH analysis is much lower than next generation 
sequencing technologies, for example, the aCGH platform used in this study, with about 
sixty thousand probes, cost only two hundred dollars per sample. Therefore, when 
considering copy number analyses of FFPE samples as well as cost effectiveness thereof, 
aCGH analysis remains an attractive even in the era of next generation sequencing.  
In conclusion, the dsDNA ratio can be used to predict the performance of DNA from 
FFPE samples on the aCGH analysis when using the ULS labeling system. Using this 
quality metric, valuable FFPE archival tissue samples can be utilized for aCGH 
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Table 1. Spearman rank correlation coefficients (rs) between DLRSpread and other 
features.  
Features rs 
A260/A280 ratio  0.237 (0.0589) 
A260/A230 ratio  -0.087 (0.4953) 
dsDNA ratio  -0.796 (<0.0001) 
Storage time (years) 0.551 (<0.0001) 
Degree of labeling (Cy5) -0.481 (<0.0001) 
P-values are shown in parentheses. A260/A280 ratio: The ratio of the absorbance at 260 
and 280nm. A260/A230 ratio: The ratio of the absorbance at 260 and 230nm. dsDNA 
ratio: The ratio of the amount of double-strand DNA and total DNA in tumor DNA.  
























































P-values are shown in parentheses. A260/A280 ratio: The ratio of the absorbance at 260 
and 280nm. A260/A230 ratio: The ratio of the absorbance at 260 and 230nm. dsDNA 
ratio: The ratio of double-strand to total DNA. 
Table 3. Partial regression coefficients of each feature in a step-wise multiple regression 
model showing the association with DLRSpread.  
Features Regression coefficient (SE) P-value 
dsDNA ratio  -0.4798 (0.0914) <0.0001 
Degree of labeling (Cy5) -0.1796 (0.0470) 0.0003 
SE: Standard error. dsDNA ratio: The ratio of double-strand to total DNA. 




dsDNA ratio  




FF 0.96 1.72 0.19 
FFPE 0.70 1.49 0.21 
WGA 0.75 1.30 0.99 
Case 31 
FF 0.77 1.74 0.17 
FFPE 0.67 1.56 0.20 
WGA 0.72 1.30 0.90 
Case 11 
FFPE 0.047 0.27 1.05 
WGA 0.20 0.31 1.07 
Case 12 
FFPE 0.035 0.28 1.04 












































1 breast 176.6 9.713 1.85 2.17 53.6 0.30 15 1.59 0.44 Present Present
2 breast 56.4 3.102 1.68 2.14 16.4 0.29 19 1.67 0.49 Present Absent
3 breast 42.8 2.354 1.7 2.01 13 0.30 34 1.87 0.68 Present Present
4 breast 170.9 9.3995 1.83 2.21 61.1 0.36 12 1.42 0.51 Absent Absent
5 breast 199 10.945 1.83 2.26 104 0.52 22 1.61 0.32 Absent Absent
6 breast 51.5 2.8325 1.77 2.01 6.33 0.12 31 1.75 0.76 Present Present
7 breast 690.1 37.9555 1.89 2.05 100 0.14 31 0.74 0.64 Absent Absent
8 breast 2114.8 116.314 1.96 2.17 176 0.08 21 0.45 0.76 Present Present
9 breast 471.7 25.9435 1.85 2.21 125 0.26 19 1.26 0.36 Absent Absent
10 breast 606.3 33.3465 1.86 2.21 107 0.18 16 0.85 0.56 Absent Absent
11 breast 691.6 38.038 1.96 2.14 32.3 0.05 33 0.27 1.05 Absent Absent
12 breast 1511.5 83.1325 1.98 2.23 50.9 0.03 31 0.28 1.04 Absent Absent
13 breast 184.1 10.1255 1.9 2.02 27 0.15 30 0.93 0.58 Absent Absent
14 breast 176.2 9.691 1.91 2.22 38.7 0.22 30 0.88 0.50 Absent Absent
15 breast 82.5 4.5375 1.79 2.14 39.9 0.48 15 1.57 0.30 Present Present
16 breast 1927.2 105.996 1.88 2.19 33 0.02 15 0.6 0.52 Absent Absent
17 breast 592.1 32.5655 1.94 2.28 163 0.28 14 1.24 0.38 Absent Absent
18 breast 246.9 13.5795 1.86 2.12 25.8 0.10 19 0.68 0.80 Present Present
19 breast 279.7 15.3835 1.95 2.11 44.4 0.16 27 0.83 0.58 Absent Absent
20 breast 237.7 13.0735 1.94 2.16 46.5 0.20 17 0.99 0.52 Present Absent
21 breast 670.2 36.861 2.01 2.08 103 0.15 15 0.78 0.75 Absent Absent
22 breast 114.7 6.3085 1.7 2.2 30.6 0.27 23 1.24 0.40 NA Present
23 breast 83.9 4.6145 1.68 1.77 9.35 0.11 28 1.01 0.48 Present Present
24 breast 67.8 3.729 1.79 2.13 31 0.46 29 1.42 0.26 NA Absent
25 breast 298.8 16.434 1.78 2.21 104 0.35 28 1.54 0.39 NA Present
26 breast 174.3 9.5865 1.76 2.23 53.8 0.31 28 1.05 0.36 Absent Absent
27 breast 94.8 5.214 1.7 2.18 24.5 0.26 43 1.34 0.52 Absent Present
28 breast 164.1 9.0255 1.8 2.17 61.4 0.37 28 1.31 0.32 Absent Absent
29 breast 119.1 6.5505 1.75 1.86 12.4 0.10 37 1.07 0.39 Absent Absent
30 breast 117 6.435 1.83 2.16 81.4 0.70 2 1.49 0.21 Present Present
31 breast 119.2 6.556 1.85 2.25 79.3 0.67 2 1.56 0.20 Present Present
32 lung 253 13.915 1.82 2.16 107 0.42 10 1.76 0.29 NA NA
33 lung 94.2 5.181 1.83 2.24 31.5 0.33 10 1.67 0.30 NA NA
34 lung 155.7 8.5635 1.89 2.26 37.3 0.24 7 1.61 0.44 NA NA
35 lung 53.8 2.959 1.82 2.15 17.9 0.33 7 1.82 0.40 NA NA
36 lung 100.9 5.5495 1.9 2.19 28.2 0.28 2 1.93 0.32 NA NA
37 lung 221.9 12.2045 1.92 2.23 77.5 0.35 2 1.64 0.27 NA NA
38 lung 71.7 3.9435 1.96 2.15 3.74 0.05 7 1.98 0.94 NA NA
39 lung 47.3 2.6015 1.89 1.95 8.01 0.17 7 2.02 0.47 NA NA
40 lung 123.9 6.8145 1.79 1.71 38.9 0.31 9 1.23 0.39 NA NA
41 lung 76.6 4.213 1.78 1.63 21.7 0.28 9 1.42 0.49 NA NA
42 lung 360.6 19.833 1.87 1.96 132 0.37 7 1.5 0.23 NA NA
43 lung 330.9 18.1995 1.9 1.69 75.1 0.23 7 1.35 0.31 NA NA
44 lung 272.9 15.0095 1.9 2.23 83.6 0.31 7 1.55 0.33 NA NA
45 lung 114.4 6.292 1.72 1.09 30.9 0.27 7 1.75 0.22 NA NA
46 lung 375.7 20.6635 1.95 2.15 103 0.27 2 1.54 0.38 NA NA
47 lung 80.5 4.4275 1.79 1.37 26.7 0.33 2 1.78 0.35 NA NA
48 lung 305.1 16.7805 1.85 1.8 17.9 0.06 8 0.58 1.01 NA NA
49 lung 207.2 11.396 1.79 1.96 39.7 0.19 8 1.11 0.51 NA NA
50 lung 1654.9 91.0195 1.92 2.27 389 0.24 7 0.78 0.34 NA NA
51 lung 230.3 12.6665 1.91 2.05 32.1 0.14 7 0.84 0.51 NA NA
52 lung 46.9 2.5795 1.76 0.92 15.9 0.34 7 1 0.47 NA NA
53 lung 57.2 3.146 1.75 1.23 22.2 0.39 7 1.53 0.39 NA NA
54 lung 630.5 34.6775 1.76 2.17 181 0.29 11 1.59 0.31 NA NA
55 lung 101 5.555 1.76 2 32 0.32 11 1.67 0.34 NA NA
56 thyroid 290.8 15.994 2 2.27 72.4 0.25 1 0.95 0.46 NA NA
57 thyroid 196.7 10.8185 1.86 1.36 116 0.59 3 1.56 0.21 NA NA
58 thyroid 279.8 15.389 1.84 2.24 196 0.70 4 1.47 0.24 NA NA
59 thyroid 164.4 9.042 1.7 1.8 129 0.78 14 1.24 0.35 NA NA
60 thyroid 110.1 6.0555 1.75 1.97 50.5 0.46 6 1.59 0.24 NA NA
61 thyroid 167.3 9.2015 1.79 1.86 78.6 0.47 7 1.53 0.21 NA NA
62 thyroid 286.8 15.774 1.99 2.22 83.2 0.29 1 1.37 0.33 NA NA
63 thyroid 158.5 8.7175 1.86 2.08 125 0.79 4 1.44 0.31 NA NA
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Figure 2. 
